title: Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: a multicenter retrospective study.
abstract: Myelodysplastic syndromes (MDS) often transform into acute leukemia (AL-MDS), although its prognostic details have not been examined thoroughly. We retrospectively analyzed the prognosis of 189 AL-MDS patients. Ninety-four patients received best supportive care (BSC), and 94 patients received disease-modifying therapies (DMT) that included chemotherapy (CHT) for 65 patients, allogeneic stem-cell transplantation (allo-SCT) for 21 patients, and other therapies for 8 patients. The median survival time was 142 days. In patients treated with BSC, platelet count alone was an independent prognostic factor. In younger patients treated with DMT (<60 years, N=25), allo-SCT was an independent prognostic factor associated with longer survival. In older patients treated with DMT (≥60 years, N=69), the therapy type did not affect survival, and performance status and MDS-specific comorbidity index were independent prognostic factors.
authors.affiliation: Division of Hematology, Department of Medicine, Nippon Medical School, Tokyo, Japan.
authors.forename: Namiko
authors.initials: N
authors.lastname: Okuyama
authors.forename: Wolfgang R
authors.initials: WR
authors.lastname: Sperr
authors.forename: Katalin
authors.initials: K
authors.lastname: Kadar
authors.forename: Sietske
authors.initials: S
authors.lastname: Bakker
authors.forename: Gergely
authors.initials: G
authors.lastname: Szombath
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Handa
authors.forename: Hideto
authors.initials: H
authors.lastname: Tamura
authors.forename: Asaka
authors.initials: A
authors.lastname: Kondo
authors.forename: Peter
authors.initials: P
authors.lastname: Valent
authors.forename: Judit
authors.initials: J
authors.lastname: Várkonyi
authors.forename: Arjan
authors.initials: A
authors.lastname: van de Loosdrecht
authors.forename: Kiyoyuki
authors.initials: K
authors.lastname: Ogata
mesh_terms: D000208:Acute Disease; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002471:Cell Transformation, Neoplastic; D004358:Drug Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D007951:Leukemia, Myeloid / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000628:therapy*; D010166:Palliative Care; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D014184:Transplantation, Homologous